vs
Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $783.7M, roughly 1.2× Insulet Corporation). Insulet Corporation runs the higher net margin — 13.0% vs 0.7%, a 12.3% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 31.2%). Insulet Corporation produced more free cash flow last quarter ($48.2M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 33.2%).
Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
ASTH vs PODD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $950.5M | $783.7M |
| Net Profit | $6.6M | $101.6M |
| Gross Margin | — | 72.6% |
| Operating Margin | 1.9% | 18.7% |
| Net Margin | 0.7% | 13.0% |
| Revenue YoY | 42.9% | 31.2% |
| Net Profit YoY | 184.4% | 0.9% |
| EPS (diluted) | $0.12 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $950.5M | $783.7M | ||
| Q3 25 | $956.0M | $706.3M | ||
| Q2 25 | $654.8M | $649.1M | ||
| Q1 25 | $620.4M | $569.0M | ||
| Q4 24 | $665.2M | $597.5M | ||
| Q3 24 | $478.7M | $543.9M | ||
| Q2 24 | $486.3M | $488.5M | ||
| Q1 24 | $404.4M | $441.7M |
| Q4 25 | $6.6M | $101.6M | ||
| Q3 25 | $373.0K | $87.6M | ||
| Q2 25 | $9.4M | $22.5M | ||
| Q1 25 | $6.7M | $35.4M | ||
| Q4 24 | $-7.8M | $100.7M | ||
| Q3 24 | $16.1M | $77.5M | ||
| Q2 24 | $19.2M | $188.6M | ||
| Q1 24 | $14.8M | $51.5M |
| Q4 25 | — | 72.6% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 69.7% | ||
| Q1 25 | — | 71.9% | ||
| Q4 24 | — | 72.1% | ||
| Q3 24 | — | 69.3% | ||
| Q2 24 | — | 67.7% | ||
| Q1 24 | — | 69.5% |
| Q4 25 | 1.9% | 18.7% | ||
| Q3 25 | 2.0% | 16.7% | ||
| Q2 25 | 3.1% | 18.7% | ||
| Q1 25 | 3.3% | 15.6% | ||
| Q4 24 | 0.1% | 18.3% | ||
| Q3 24 | 5.9% | 16.2% | ||
| Q2 24 | 6.2% | 11.2% | ||
| Q1 24 | 7.5% | 12.9% |
| Q4 25 | 0.7% | 13.0% | ||
| Q3 25 | 0.0% | 12.4% | ||
| Q2 25 | 1.4% | 3.5% | ||
| Q1 25 | 1.1% | 6.2% | ||
| Q4 24 | -1.2% | 16.9% | ||
| Q3 24 | 3.4% | 14.2% | ||
| Q2 24 | 3.9% | 38.6% | ||
| Q1 24 | 3.7% | 11.7% |
| Q4 25 | $0.12 | $1.42 | ||
| Q3 25 | $0.01 | $1.24 | ||
| Q2 25 | $0.19 | $0.32 | ||
| Q1 25 | $0.14 | $0.50 | ||
| Q4 24 | $-0.14 | $1.38 | ||
| Q3 24 | $0.33 | $1.08 | ||
| Q2 24 | $0.40 | $2.59 | ||
| Q1 24 | $0.31 | $0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $429.5M | — |
| Total DebtLower is stronger | — | $930.8M |
| Stockholders' EquityBook value | $779.3M | $1.5B |
| Total Assets | $2.2B | $3.2B |
| Debt / EquityLower = less leverage | — | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $429.5M | — | ||
| Q3 25 | $463.4M | — | ||
| Q2 25 | $342.1M | — | ||
| Q1 25 | $260.9M | — | ||
| Q4 24 | $290.8M | — | ||
| Q3 24 | $350.3M | — | ||
| Q2 24 | $327.7M | — | ||
| Q1 24 | $337.3M | — |
| Q4 25 | — | $930.8M | ||
| Q3 25 | — | $934.9M | ||
| Q2 25 | — | $939.0M | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B | ||
| Q1 24 | — | $1.4B |
| Q4 25 | $779.3M | $1.5B | ||
| Q3 25 | $775.5M | $1.4B | ||
| Q2 25 | $765.5M | $1.5B | ||
| Q1 25 | $745.4M | $1.3B | ||
| Q4 24 | $712.7M | $1.2B | ||
| Q3 24 | $704.6M | $1.1B | ||
| Q2 24 | $678.9M | $998.4M | ||
| Q1 24 | $653.5M | $790.7M |
| Q4 25 | $2.2B | $3.2B | ||
| Q3 25 | $2.2B | $3.0B | ||
| Q2 25 | $1.4B | $3.5B | ||
| Q1 25 | $1.3B | $3.5B | ||
| Q4 24 | $1.4B | $3.1B | ||
| Q3 24 | $1.3B | $3.0B | ||
| Q2 24 | $1.3B | $2.9B | ||
| Q1 24 | $1.2B | $2.6B |
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.68× | ||
| Q2 25 | — | 0.64× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.21× | ||
| Q2 24 | — | 1.36× | ||
| Q1 24 | — | 1.72× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.9M | $183.3M |
| Free Cash FlowOCF − Capex | $-6.0M | $48.2M |
| FCF MarginFCF / Revenue | -0.6% | 6.2% |
| Capex IntensityCapex / Revenue | 0.3% | 17.2% |
| Cash ConversionOCF / Net Profit | -0.44× | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | $104.5M | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.9M | $183.3M | ||
| Q3 25 | $10.0M | $125.7M | ||
| Q2 25 | $90.9M | $196.5M | ||
| Q1 25 | $16.6M | $63.8M | ||
| Q4 24 | $-10.9M | $147.7M | ||
| Q3 24 | $34.0M | $98.5M | ||
| Q2 24 | $23.2M | $96.5M | ||
| Q1 24 | $6.0M | $87.6M |
| Q4 25 | $-6.0M | $48.2M | ||
| Q3 25 | $7.4M | $100.1M | ||
| Q2 25 | $89.5M | $177.9M | ||
| Q1 25 | $13.6M | $51.5M | ||
| Q4 24 | $-13.5M | $94.1M | ||
| Q3 24 | $31.7M | $71.8M | ||
| Q2 24 | $20.4M | $74.0M | ||
| Q1 24 | $5.6M | $65.5M |
| Q4 25 | -0.6% | 6.2% | ||
| Q3 25 | 0.8% | 14.2% | ||
| Q2 25 | 13.7% | 27.4% | ||
| Q1 25 | 2.2% | 9.1% | ||
| Q4 24 | -2.0% | 15.7% | ||
| Q3 24 | 6.6% | 13.2% | ||
| Q2 24 | 4.2% | 15.1% | ||
| Q1 24 | 1.4% | 14.8% |
| Q4 25 | 0.3% | 17.2% | ||
| Q3 25 | 0.3% | 3.6% | ||
| Q2 25 | 0.2% | 2.9% | ||
| Q1 25 | 0.5% | 2.2% | ||
| Q4 24 | 0.4% | 9.0% | ||
| Q3 24 | 0.5% | 4.9% | ||
| Q2 24 | 0.6% | 4.6% | ||
| Q1 24 | 0.1% | 5.0% |
| Q4 25 | -0.44× | 1.80× | ||
| Q3 25 | 26.69× | 1.43× | ||
| Q2 25 | 9.65× | 8.73× | ||
| Q1 25 | 2.48× | 1.80× | ||
| Q4 24 | — | 1.47× | ||
| Q3 24 | 2.11× | 1.27× | ||
| Q2 24 | 1.21× | 0.51× | ||
| Q1 24 | 0.40× | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
